Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e8d2afa63dbd8bbb90545722d3f54c1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-18 |
filingDate |
2015-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81f5433c09845a52a1c229428642ba5f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd4d317b72ea7b09838e3ea8fd005eca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3f9c1bcdd3ad4cdc44c460a654bbd8b |
publicationDate |
2016-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2016074703-A |
titleOfInvention |
Pancreatic cancer treatment |
abstract |
A novel therapeutic agent for pancreatic cancer is provided. A composition for treating pancreatic cancer comprising an IL-6 inhibitor, which contains an antimetabolite or is administered in combination with an antimetabolite. Preferably, the IL-6 inhibitor is a substance that binds to an IL-6 receptor such as an anti-IL-6 receptor antibody, and the antimetabolite is a cytosine analog such as gemcitabine. [Effect] Reduction of metastatic focus and disappearance of ascites from human pancreatic cancer. [Selection figure] None |
priorityDate |
2010-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |